Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Emilie A Chapeau"'
Autor:
Emilie A Chapeau, Emeline Mandon, Jason Gill, Vincent Romanet, Nicolas Ebel, Violetta Powajbo, Rita Andraos-Rey, Zhiyan Qian, Miltos Kininis, Sabine Zumstein-Mecker, Moriko Ito, Nancy E Hynes, Ralph Tiedt, Francesco Hofmann, Leonid Eshkind, Ernesto Bockamp, Bernd Kinzel, Matthias Mueller, Masato Murakami, Fabienne Baffert, Thomas Radimerski
Publikováno v:
PLoS ONE, Vol 14, Iss 10, p e0221635 (2019)
Aberrant activation of the JAK/STAT pathway is thought to be the critical event in the pathogenesis of the chronic myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia and primary myelofibrosis. The most frequent genetic alterat
Externí odkaz:
https://doaj.org/article/a9675b428fbc4f1489023b4044ed239c
Autor:
William R. Sellers, Francesco Hofmann, Michael R. Jensen, Marion Wiesmann, Emil Kuriakose, Audrey Kauffmann, Astrid Jullion, Ensar Halilovic, Nelson Guerreiro, Jens Würthner, Pascal Furet, Joerg Kallen, Therese-Marie Stachyra, Stephan Ruetz, Marta Cortes-Cros, Swann Gaulis, Eric Y. Durand, Grainne Kerr, Masato Murakami, Vincent Romanet, Dario Sterker, Markus Wartmann, Emilie A. Chapeau, Jeanette Fuchs, Philipp Holzer, Stéphane Ferretti, Sébastien Jeay
Median of the shRNAs and RSA values. File containing median counts and log fold changes of each gene from Supplementary Data File S1. According significance values of each gene as activator or sensitizer compared to DMSO control (see Methods) are inc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9fb2879a6749b92d41888b92af04a38
https://doi.org/10.1158/0008-5472.22420067.v1
https://doi.org/10.1158/0008-5472.22420067.v1
Autor:
William R. Sellers, Francesco Hofmann, Michael R. Jensen, Marion Wiesmann, Emil Kuriakose, Audrey Kauffmann, Astrid Jullion, Ensar Halilovic, Nelson Guerreiro, Jens Würthner, Pascal Furet, Joerg Kallen, Therese-Marie Stachyra, Stephan Ruetz, Marta Cortes-Cros, Swann Gaulis, Eric Y. Durand, Grainne Kerr, Masato Murakami, Vincent Romanet, Dario Sterker, Markus Wartmann, Emilie A. Chapeau, Jeanette Fuchs, Philipp Holzer, Stéphane Ferretti, Sébastien Jeay
Supplementary material and methods include the description for the bioanalytical method for HDM201 detection in plasma and tumor, the human and mouse gene expression analysis in vitro and in vivo, the live-cell quantification of cleaved-caspase activ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b82fed93efadb9ad16a5268c6dd4a1d
https://doi.org/10.1158/0008-5472.22420061
https://doi.org/10.1158/0008-5472.22420061
Autor:
John C. Reed, Juan M. Zapata, Christina Kress, Benjamin Faustin, Jean-Marie Bruey, Nathalie Droin, Fréderic Luciano, Emilie Bard-Chapeau, Béatrice Bailly-Maitre
The liver has enormous regenerative capacity such that, after partial hepatectomy, hepatocytes rapidly replicate to restore liver mass, thus providing a context for studying in vivo mechanisms of cell growth regulation. Bax inhibitor-1 (BI-1) is an e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3120e43a504573f07d1bbef35939220f
https://doi.org/10.1158/0008-5472.c.6495128
https://doi.org/10.1158/0008-5472.c.6495128
Autor:
John C. Reed, Juan M. Zapata, Christina Kress, Benjamin Faustin, Jean-Marie Bruey, Nathalie Droin, Fréderic Luciano, Emilie Bard-Chapeau, Béatrice Bailly-Maitre
Supplementary Figures 1-5 from Mice Lacking bi-1 Gene Show Accelerated Liver Regeneration
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66fd95cda40d7c5a0e0c9a8ca55c2c40
https://doi.org/10.1158/0008-5472.22366412.v1
https://doi.org/10.1158/0008-5472.22366412.v1
Autor:
John C. Reed, Juan M. Zapata, Christina Kress, Benjamin Faustin, Jean-Marie Bruey, Nathalie Droin, Fréderic Luciano, Emilie Bard-Chapeau, Béatrice Bailly-Maitre
Supplementary Figure Legends 1-5 from Mice Lacking bi-1 Gene Show Accelerated Liver Regeneration
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0fec70091da6395f3f7db3751668fae
https://doi.org/10.1158/0008-5472.22366415.v1
https://doi.org/10.1158/0008-5472.22366415.v1
Autor:
Emil T. Kuriakose, Vincent Romanet, Swann Gaulis, Philipp Holzer, Grainne Kerr, Nelson Guerreiro, Dario Sterker, Emilie A. Chapeau, Astrid Jullion, Jeanette Fuchs, Francesco Hofmann, Sébastien Jeay, Jens Würthner, Masato Murakami, Joerg Kallen, Stephan Ruetz, Audrey Kauffmann, Marta Cortes-Cros, Pascal Furet, Therese-Marie Stachyra, William R. Sellers, Markus Wartmann, Michael Rugaard Jensen, Marion Wiesmann, Eric Durand, Stephane Ferretti, Ensar Halilovic
Publikováno v:
Cancer Research. 78:6257-6267
Activation of p53 by inhibitors of the p53–MDM2 interaction is being pursued as a therapeutic strategy in p53 wild-type cancers. Here, we report distinct mechanisms by which the novel, potent, and selective inhibitor of the p53–MDM2 interaction H
Publikováno v:
Current opinion in geneticsdevelopment. 54
Acquired resistance is a major limitation for the successful treatment of cancer patients. Although numerous efficacious cancer therapeutics have been developed in the past decades, resistance arises due to a variety of reasons including tumoral gene
Autor:
Vincent Romanet, Marion Wiesmann, Roland Rad, Eric Durand, William R. Sellers, Audrey Kauffmann, Sébastien Jeay, Francesco Hofmann, Armelle Grevot, Agnieszka Gembarska, Antoine de Weck, Emeline Mandon, Ralph Tiedt, Louise Barys, Esther Sutter, Michael Rugaard Jensen, Stephane Ferretti, Masato Murakami, Pierre Moulin, Joseph Lehar, Emilie A. Chapeau, Claire Estadieu
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America. 114(12)
Inhibitors of double minute 2 protein (MDM2)-tumor protein 53 (TP53) interaction are predicted to be effective in tumors in which the TP53 gene is wild type, by preventing TP53 protein degradation. One such setting is represented by the frequent CDKN
Autor:
Emilie A. Chapeau
Publikováno v:
Cancer Research. 78:5908-5908
Inhibitors of MDM2-TP53 interaction are predicted to be effective in tumors where the TP53 gene is wild-type by preventing TP53 protein degradation. One such setting is represented by the frequent CDKN2A deletion in human cancer that, through inactiv